WO2010036052A3 - 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 조성물 - Google Patents

4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 조성물 Download PDF

Info

Publication number
WO2010036052A3
WO2010036052A3 PCT/KR2009/005485 KR2009005485W WO2010036052A3 WO 2010036052 A3 WO2010036052 A3 WO 2010036052A3 KR 2009005485 W KR2009005485 W KR 2009005485W WO 2010036052 A3 WO2010036052 A3 WO 2010036052A3
Authority
WO
WIPO (PCT)
Prior art keywords
methylhonokiol
related diseases
amyloid
present
treating
Prior art date
Application number
PCT/KR2009/005485
Other languages
English (en)
French (fr)
Other versions
WO2010036052A2 (ko
Inventor
김기호
김기수
김영희
김진국
김경태
한창성
이상일
Original Assignee
주식회사 바이오랜드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020080094320A external-priority patent/KR100926466B1/ko
Priority claimed from KR1020080094273A external-priority patent/KR100932962B1/ko
Application filed by 주식회사 바이오랜드 filed Critical 주식회사 바이오랜드
Priority to JP2011528940A priority Critical patent/JP5514827B2/ja
Priority to CN200980137230XA priority patent/CN102159199B/zh
Priority to US13/120,818 priority patent/US8604087B2/en
Priority to EP09816445.2A priority patent/EP2327402B1/en
Publication of WO2010036052A2 publication Critical patent/WO2010036052A2/ko
Publication of WO2010036052A3 publication Critical patent/WO2010036052A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 4-O-메틸호노키올을 유효성분으로 하는 아밀로이드 관련 질환의 치료 또는 예방용 조성물에 관한 것으로, 더욱 구체적으로는 4-O-메틸호노키올(4-O-Methylhonokiol)을 유효성분으로 함유하는 알츠하이머병, 인지장애, 기억력 감퇴 및 아밀로이드증 등 아밀로이드 관련 질환의 치료 또는 예방에 유용한 약제 조성물에 관한 것이다. 본 발명자들은 본 발명의 4-O-메틸호노키올이 베타-아밀로이드 형성을 억제한다는 사실을 처음으로 밝혀내어 아밀로이드 관련 질환의 치료 및 예방에 사용될 수 있음을 확인하였으며, 실험쥐를 이용한 수중미로 시험, 수동적 회피 시험 등의 동물실험을 실시하여 4-O-메틸호노키올이 아밀로이드 관련 질환인 알츠하이머병, 인지장애, 기억력 감퇴 및 아밀로이드증 등에 효능이 있음을 확인하였고, 쥐의 뇌에서 피질과 해마조직을 이용한 아세틸콜린 분해효소 활성억제 시험을 통하여 아밀로이드 관련 질환 중에서도 알츠하이머병의 치료 또는 예방에 더욱 효과적임을 추가적으로 확인하였다.
PCT/KR2009/005485 2008-09-25 2009-09-25 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 조성물 WO2010036052A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2011528940A JP5514827B2 (ja) 2008-09-25 2009-09-25 ４−ｏ−メチルホノキオールを含有するアミロイド関連疾患の治療又は予防用組成物
CN200980137230XA CN102159199B (zh) 2008-09-25 2009-09-25 用于治疗或预防淀粉样蛋白相关疾病的包含4-o-甲基和厚朴酚的组合物
US13/120,818 US8604087B2 (en) 2008-09-25 2009-09-25 Composition for treating or preventing amyloid-related diseases comprising 4-O-methylhonokiol
EP09816445.2A EP2327402B1 (en) 2008-09-25 2009-09-25 Composition containing 4-o-methylhonokiol for treating or preventing amyloid- related diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2008-0094320 2008-09-25
KR1020080094320A KR100926466B1 (ko) 2008-09-25 2008-09-25 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 약제 조성물
KR1020080094273A KR100932962B1 (ko) 2008-09-25 2008-09-25 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 개선 또는 예방용 기능성 식품조성물
KR10-2008-0094273 2008-09-25

Publications (2)

Publication Number Publication Date
WO2010036052A2 WO2010036052A2 (ko) 2010-04-01
WO2010036052A3 true WO2010036052A3 (ko) 2010-07-22

Family

ID=42060292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/005485 WO2010036052A2 (ko) 2008-09-25 2009-09-25 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 조성물

Country Status (5)

Country Link
US (1) US8604087B2 (ko)
EP (1) EP2327402B1 (ko)
JP (1) JP5514827B2 (ko)
CN (1) CN102159199B (ko)
WO (1) WO2010036052A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2705027T3 (es) 2010-08-19 2019-03-21 Buck Institute For Age Res Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
CN102178666B (zh) * 2011-03-21 2014-06-18 四川大学 和厚朴酚在制备预防或治疗颅内占位性病变和颅内组织器官炎症的药物中的用途
EP2814491A4 (en) * 2012-02-18 2015-08-26 Buck Inst For Res On Aging FORMULATIONS AND METHODS FOR TREATING OR PROPHYLAXIS OF PRE-MCI AND / OR PRE-ALZHEIMER ILLNESSES
US9486419B2 (en) 2013-04-17 2016-11-08 Ariel-University Research And Development Company CB2 receptor ligands for the treatment of psychiatric disorders
CN105622603A (zh) * 2015-05-28 2016-06-01 广州牌牌生物科技有限公司 多核化合物、其制备方法以及其应用
WO2018112138A1 (en) * 2016-12-15 2018-06-21 Anavi Goffer Sharon Treatment of mental, movement and behavioral disorders
CN108283630A (zh) * 2017-01-08 2018-07-17 杨丽华 和厚朴酚在血管性痴呆药物中的应用
EP4021379A1 (en) 2019-08-29 2022-07-06 Kao Corporation Composition, process and kit for semi-permanent straightening and curling of keratin fibers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382213B1 (en) * 1989-02-08 1995-05-10 Otsuka Pharmaceutical Co., Ltd. Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
JP2003048844A (ja) * 2001-08-03 2003-02-21 Yakult Honsha Co Ltd ウレアーゼ活性阻害剤
JP2006347940A (ja) * 2005-06-15 2006-12-28 Tsumura & Co βアミロイド生成抑制剤
WO2008074896A1 (en) * 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
KR100975819B1 (ko) 2008-03-04 2010-08-16 주식회사 바이오랜드 후박 추출물 또는 이로부터 분리된 ４―０―메틸호노키올을함유하는 탈모 방지 및 모발 생장 촉진용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382213B1 (en) * 1989-02-08 1995-05-10 Otsuka Pharmaceutical Co., Ltd. Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ESUMI T. ET AL: "Efficient synthesis and structure-activity relationship of honokiol, a neurotrophic biphenyl-type neolignan", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 2621 - 2625, XP004841253 *
HOUGHTON P. J. ET AL: "Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease", NEUROSIGNALS, vol. 14, 2005, pages 6 - 12, XP008144181 *
LIN Y.R.: "Neuroprotective and antinociceptive properties of honokiol and magnolol: evidence for participation of glutamate receptor-mediated pathway", 2006, TZU CHI UNIVERSITY, XP008144182 *

Also Published As

Publication number Publication date
WO2010036052A2 (ko) 2010-04-01
US20110207830A1 (en) 2011-08-25
JP2012503649A (ja) 2012-02-09
EP2327402A4 (en) 2013-08-07
CN102159199B (zh) 2012-11-21
JP5514827B2 (ja) 2014-06-04
EP2327402A2 (en) 2011-06-01
EP2327402B1 (en) 2014-07-23
CN102159199A (zh) 2011-08-17
US8604087B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
WO2010036052A3 (ko) 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 조성물
BRPI0520588A2 (pt) composições farmacêuticas para o tratamento de distúrbios do ouvido interno
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
WO2008070670A3 (en) Enhanced immediate release formulations of topiramate
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
UA83899C2 (uk) Сполуки імідазолу для лікування нейродегенеративних розладів
WO2008011476A3 (en) Compositions and methods for modulating sirtuin activity
WO2009035473A3 (en) Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
WO2007005961A3 (en) Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2007006003A3 (en) Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
EP2977452A3 (en) Methods of treatment and prevention of neurodegenerative diseases and disorders
WO2007087151A3 (en) Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
BR112013003847A8 (pt) métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
WO2007005940A3 (en) Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
ATE445401T1 (de) Verwendung von opioid-rezeptorantagonisten zur prävention und/oder behandlung von erkrankungen im zusammenhang mit dem target calcineurin
BRPI0407832A (pt) inibidor de pten ou abridor dos canais maxi-k
WO2003070728A3 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
ATE237341T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l- carnitin derivate und ginkgo biloba extrakte
WO2005095348A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
WO2006101910A3 (en) Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980137230.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09816445

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009816445

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011528940

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 13120818

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE